Canopy Growth Stock Falls From $500 to $1 as Turnaround Prospects Dim

Stock Price Trajectory and Reverse-Split History

Canopy Growth's nominal share price has been artificially supported by at least two reverse stock splits since 2022, masking a near-total erosion of market capitalization. Shares that traded above $500 in early 2018—during the Canadian legalization euphoria—now trade at approximately $1.00 on a split-adjusted basis. A 99.8% decline. The company executed a 10-for-1 reverse split in December 2023 and a subsequent consolidation in 2025, both aimed at maintaining Nasdaq listing compliance.

Market capitalization has contracted from a 2018 peak exceeding $15 billion to an estimated $150 million to $200 million today, depending on outstanding share count after dilutive financings. The decline outpaces most North American cannabis operators, including U.S. multi-state operators constrained by federal prohibition and IRC §280E tax burdens.

Operating Performance and Path to Profitability

Canopy Growth has reported consecutive quarterly losses since 2019, with restructuring charges and impairment write-downs exceeding $2 billion cumulatively. The company's most recent fiscal quarter showed:

• Net revenue of approximately CAD $65 million, down 18% year-over-year
• Adjusted EBITDA loss of CAD $22 million, an improvement from CAD $45 million in the prior-year period
• Cash burn rate of approximately CAD $15 million per month, supported by a Constellation Brands credit facility
• Gross margin compression to 8-12% on cannabis operations, below the 35-50% range typical of profitable Canadian LPs

Management has targeted positive free cash flow by Q4 fiscal 2027, contingent on facility consolidations and SKU rationalization. That timeline assumes no further impairment charges and stable pricing in Canadian recreational markets—both of which remain uncertain, according to the company's disclosure.

Canopy continues to operate under a going-concern qualification in audited financials, citing liquidity risk and dependence on external financing. Constellation Brands, which invested over $4 billion in Canopy Growth between 2017 and 2019, has written down its stake to near-zero carrying value.

Investor Thesis and Downside Scenarios

The bull case hinges on U.S. federal rescheduling or legalization unlocking Canopy Growth's dormant U.S. optionality, but the company's balance sheet may not survive the wait. Canopy holds licenses and IP for U.S. market entry through subsidiaries structured to comply with current law. Activation requires either:

• Cannabis removal from Schedule I (enabling cross-border commerce), or
• U.S. federal legalization permitting direct THC operations by foreign entities

Neither event is imminent. The DEA's 2024 denial of rescheduling petitions and congressional gridlock on the SAFE Banking Act suggest a timeline extending into 2028 or beyond. Canopy's monthly cash burn implies the company will require additional equity or debt financing before any U.S. catalyst materializes. Further dilution for existing shareholders.

The bear case is mechanical: continued losses, dilution, and eventual delisting or acquisition at distressed valuations. Comparable Canadian LPs including Hexo and Sundial have faced similar trajectories—Hexo entered creditor protection in 2023 and Sundial pivoted to investment operations after operational failures.

We'll be watching Canopy's Q3 fiscal 2027 earnings in February for updated cash runway guidance and any signals of accelerated facility closures. For background on cannabis equity valuation dynamics and sector-wide capital destruction, see the CannIntel topic hub on Canopy Growth stock analysis.